Law360, New York (May 28, 2009, 12:00 AM ET) -- The U.S. Patent and Trademark Office has granted a request to re-examine a Merck & Co. patent covering blockbuster allergy drug Singulair that is at the center of a patent dispute between the company and generic drugmaker Teva Pharmaceutical Industries Ltd.
The patent authority granted the request on May 20, according to a letter filed Thursday in the U.S. District Court of New Jersey by Teva Pharmaceutical Industries Ltd.’s attorney Michael Patunas of Lite DePalma Greenberg & Rivas LLC. The re-examination request was filed by Article...
USPTO Grants Re-Exam Of Merck Singulair Patent
To view the full article, take a free trial now.
